The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - MSD; Myriad Genetics; NeraCare GmbH; Novartis
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
 
Irene Reijers
No Relationships to Disclose
 
Elisa A. Rozeman
Travel, Accommodations, Expenses - MSD; NanoString Technologies
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Bart A. Van De Wiel
No Relationships to Disclose
 
Hanna Eriksson
No Relationships to Disclose
 
Karijn Suijkerbuijk
No Relationships to Disclose
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Roche
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
 
Willem M.C. Klop
No Relationships to Disclose
 
Andrew Spillane
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Inge Marie Svane
Honoraria - Abbvie; Bristol-Myers Squibb; Genentech; Incyte; MSD; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Incyte; MSD; Novartis; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer
 
Lars Bastholt
No Relationships to Disclose
 
Henrik Schmidt
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis
Research Funding - MSD
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)
 
Christian U. Blank
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb